{"filing":{"accession_number":"0001193125-26-248244","cik":"0001885522","ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"d18793d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526248244/d18793d8k.htm"},"events":[{"id":8114,"run_id":7122,"accession_number":"0001193125-26-248244","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure reports the complete tabulation of stockholder votes from Neumora's Annual Meeting of Stockholders held on May 27, 2026, covering four proposals: election of three Class III directors, ratification of Ernst \u0026 Young LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote on frequency of future compensation votes. The filing presents vote counts (For, Against, Withheld, Abstentions, and Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results disclosures required under Item 5.07.","company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","filing_date":"2026-05-29","form":"8-K","submitted_at":null,"items":[{"id":2708,"accession_number":"0001193125-26-248244","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the complete tabulation of stockholder votes from Neumora's Annual Meeting of Stockholders held on May 27, 2026, covering four proposals: election of three Class III directors, ratification of Ernst \u0026 Young LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote on frequency of future compensation votes. The filing presents vote counts (For, Against, Withheld, Abstentions, and Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results disclosures required under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:13:08.513330+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2708,"accession_number":"0001193125-26-248244","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the complete tabulation of stockholder votes from Neumora's Annual Meeting of Stockholders held on May 27, 2026, covering four proposals: election of three Class III directors, ratification of Ernst \u0026 Young LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote on frequency of future compensation votes. The filing presents vote counts (For, Against, Withheld, Abstentions, and Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results disclosures required under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:13:08.513330+00:00","company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","filing_date":"2026-05-29"}]}